Episode Details

Celcuity, a clinical-stage biotech, reported a narrower net loss than expected for Q4 2025, at $38.4 million, or $0.73 per share, compared to the forecasted $1.05 per share. The company ended the year with a strong cash position of nearly $166 million, up from $22.5 million at the start of 2025. Topline data from the phase three trial of its drug gedatolisib for advanced breast cancer is expected in Q2 2026.

Support the show:
Get a discount at https://solipillow.com/discount/dnn.

Advertise on DNN:
advertise@thednn.ai

This is an automated, high-level news summary based on public reporting.
Report issues to feedback@thednn.ai.

View sources & latest updates:
https://sources.thednn.ai/65ead799212e2446